drugset / Trial / NCT01614782
A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess the multiple rising dose safety/tolerability and pharmacokinetics of MK-5823 in overweight/obese participants who are healthy and overweight/obese participants with Type 2 diabetes mellitus (T2DM).
Timeline
- Start
- 2012-06
- Primary completion
- 2012-10
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-5823 | Unknown | 0.35 mg | Subcutaneous |
| Subject | MK-5823 | Unknown | 0.7 mg | Subcutaneous |
| Subject | MK-5823 | Unknown | 1.4 mg | Subcutaneous |
| Subject | MK-5823 | Unknown | 2.8 mg | Subcutaneous |